Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Kravchenko, Julia ^a   Akushevich, Igor ^b   Sudenga, Staci L ^c   Wilson, Craig M ^c   Levitan, Emily B ^c   Shrestha, Sadeep ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 56; MAJOR CLINICAL STUDY; MOLECULAR PHYLOGENY; PAPILLOMAVIRUS INFECTION; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SPECIES DIFFERENTIATION; VIRAL CLEARANCE; VIRUS LOAD; WART VIRUS; ALGORITHM; ALPHAPAPILLOMAVIRUS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INCIDENCE; MIXED INFECTION; PHYSIOLOGY; PREVALENCE; PROBABILITY; STATISTICS; THEORETICAL MODEL; VIROLOGY; VIRUS INTERFERENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS;

ADOLESCENT; ALGORITHMS; ALPHAPAPILLOMAVIRUS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROBABILITY; VIRAL INTERFERENCE; VIRAL LOAD;

EID: 84856170157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030736     Document Type: Article

References (53)

1. Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, et al. (2000) Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and-seronegative women. Am J Epidemiol 151: 1148-1157.
2. Moscicki AB, Ellenberg JH, Farhat S, Xu J, (2004) Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 190: 37-45.
3. Schiffman MH, Castle P, (2003) Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 95: E2.
4. Woodman CB, Collins SI, Young LS, (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7: 11-22.
5. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365-1371.
6. Kulmala SM, Shabalova IP, Petrovitchev N, Syrjanen KJ, Gyllensten UB, et al. (2007) Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 16: 17-22.
7. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, et al. (2002) Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Bmj 325: 572.
8. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, et al. (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358: 1782-1783.
9. Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, et al. (1998) Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 25: 243-250.
10. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, et al. (1998) The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health 22: 300-311.
11. Shrestha S, Sudenga SL, Smith JS, Bachmann LH, Wilson CM, et al. (2010) The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis 10: 295.
12. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, et al. (2000) Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 154: 127-134.
13. Van Ranst M, Kaplan JB, Burk RD, (1992) Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 73 (Pt 10): 2653-2660.
14. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, (2001) Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 13: 27-40.
15. Bonney GE, (1987) Logistic regression for dependent binary observations. Biometrics 43: 951-973.
16. Taubman SL, Robins JM, Mittleman MA, Hernan MA, (2009) Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol 38: 1599-1611.
17. Kong X, Archer KJ, Moulton LH, Gray RH, Wang MC, (2010) Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance. BMC Medical Research Methodology 10: 40.
18. Lehtinen M, Luukkaala T, Wallin KL, Paavonen J, Thoresen S, et al. (2001) Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 22: 117-124.
19. Hosmer DW, Lemeshow S, (2000) Applied Logistic Regression. New York Wiley.
20. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, et al. (2005) Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. Jama 293: 1471-1476.
21. Clark RA, Brandon W, Dumestre J, Pindaro C, (1993) Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. Clin Infect Dis 17: 165-172.
22. Shrestha S, Wang C, Aissani B, Wilson CM, Tang J, et al. (2007) Interleukin-10 gene (IL10) Polymorphisms and Human Papillomavirus Clearance among Immunosuppressed Adolescents. Cancer Epidemiology Biomarkers and Prevention 16: 1-7.
23. Khanna N, (2002) HAART use in women with HIV and influence on cervical intraepithelial neoplasia: a clinical opinion. J Low Genit Tract Dis 6: 111-115.
24. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, et al. (2001) Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 184: 682-690.
25. Williams DA, (1975) The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. Biometrics 31: 949-952.
26. Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 19: 159-169.
27. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, et al. (1997) Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. The Journal of infectious diseases 175: 927-931.
28. Sobhani I, Walker F, Roudot-Thoraval F, Abramowitz L, Johanet H, et al. (2004) Anal carcinoma: incidence and effect of cumulative infections. Aids 18: 1561-1569.
29. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, et al. (1997) Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337: 1343-1349.
30. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, et al. (2004) Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 190: 1413-1421.
31. Vermund SH, Kelley KF, Klein RS, Feingold AR, Schreiber K, et al. (1991) High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 165: 392-400.
32. Denny L, Boa R, Williamson AL, Allan B, Hardie D, et al. (2008) Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 111: 1380-1387.
33. Sun XW, Ellerbrock TV, Lungu O, Chiasson MA, Bush TJ, et al. (1995) Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 85: 680-686.
34. Fennema JS, van Ameijden EJ, Coutinho RA, van den Hoek AA, (1995) HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. Aids 9: 1071-1078.
35. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, et al. (2003) Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158: 486-494.
36. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, et al. (2003) Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 95: 1062-1071.
37. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, et al. (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337: 76-84.
38. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, et al. (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180: 1415-1423.
39. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, et al. (2006) Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 119: 1623-1629.
40. Rowhani-Rahbar A, Hawes SE, Sow PS, Toure P, Feng Q, et al. (2007) The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 196: 887-894.
41. Crowley-Nowick PA, Ellenberg JH, Vermund SH, Douglas SD, Holland CA, et al. (2000) Cytokine profile in genital tract secretions from female adolescents: impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J Infect Dis 181: 939-945.
42. Silverberg MJ, Schneider MF, Silver B, Anastos KM, Burk RD, et al. (2006) Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clinical and vaccine immunology: CVI 13: 511-519.
43. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, et al. (2002) Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360: 228-229.
44. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, et al. (2001) Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 184: 547-551.
45. Rosenblatt A, Guidi HGC, (2009) Human papillomavirus infection in HIV-infected individuals Human Papillomavirus: Springer-Verlag Berlin and Heidelberg GmbH & Co. K pp. 163-177.
46. Hampson L, Kitchener HC, Hampson IN, (2006) Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antiviral Therapy 11: 813-825.
47. Johansson M, Schon K, Ward M, Lycke N, (1997) Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans? Scandinavian Journal of Immunology 46: 546-552.
48. Su H, Caldwell HD, (1995) CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infection and Immunity 63: 3302-3308.
49. Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, et al. (2000) Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. International journal of cancer Journal international du cancer 85: 35-39.
50. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD, (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428.
51. Yashin AI, Arbeev KG, Akushevich I, Kulminski A, Akushevich L, et al. (2007) Stochastic model for analysis of longitudinal data on aging and mortality. Mathematical Biosciences 208: 538-551.
52. Yashin AI, Manton KG, (1997) Effects of unobserved and partially covariate processes on system failure: A review of Models and estimation strategies. Statistical Science 12: 20-34.
53. Akushevich I, Kulminski A, Manton K, (2005) Life Tables with Covariates: Dynamic Model for Nonlinear Analysis of Longitudinal Data. Mathematical Population Studies 12: 51-80.